results; the ability of the current model of genetic counseling practices to deal with the increase in patient volume; and the cost-effectiveness of such an approach. 8 , 9 One way of minimizing the identification of VUS, the impact of false
Search Results
Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time
Filipa Lynce and Claudine Isaacs
Your Genes: Getting the Best Fit
Margaret Tempero
reducing lifestyle risks that they can actually control? Considering the expanding need, the workforce shortage in genetic counseling is increasing to epic proportions, and I don't think there is a solution in sight. So I guess this is another call to
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative
Julia R. Trosman, Christine B. Weldon, Michael P. Douglas, Allison W. Kurian, R. Kate Kelley, Patricia A. Deverka, and Kathryn A. Phillips
despite informed consent and genetic counseling, patients may not understand the immature state of evidence about numerous genes within panels (73%) and that their data are used for research, to which many would object if better informed. Payers' suspicion
A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer
Sean Dineen, Patrick M. Lynch, Miguel A. Rodriguez-Bigas, Sarah Bannon, Melissa Taggart, Colleen Reeves, Cathy Modaro, Michael Overman, George J. Chang, John M. Skibber, and Y. Nancy You
chemotherapy regimens. 20 However, in practice, adherence to this guideline is poor, 21 , 22 and many patients are not referred for genetic counseling and workup. 23 We hypothesized that system-based practice intervention, designed with the Six Sigma quality
Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
Maxim Ivanov, Margarita Sharova, Andrea Olsen, Alexandra Lebedeva, Ekaterina Ignatova, Gerald Mouse, and Vladislav Mileyko
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 1 provide substantial groundwork for specialist practice in diverse fields: medical oncology, genetic
Implementation of INHERET, an Online Family History and Cancer Risk Interpretation Program for Primary Care and Specialty Clinics
Lynn A. McCain, Kara J. Milliron, Amanda M. Cook, Robert Paquette, Jasmine B. Parvaz, Susan D. Ernst, Anne L. Kittendorf, Diane M. Harper, Philip Zazove, Jim Arthurs, Jerry A. Tippie, Bailey Hulswit, Lee F. Schroeder, David F. Keren, and Sofia D. Merajver
genetic counseling. In an integrated health system, 6 <30% of patients had family history documented in the medical record. As a result, there is a pressing need to improve genetics clinics’ efficiency, given the increasing number of patients being
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Featured Updates to the NCCN Guidelines
Mary B. Daly, Robert Pilarski, Matthew B. Yurgelun, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Judy E. Garber, Michael Goggins, Mollie L. Hutton, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Tuya Pal, Holly J. Pederson, Gwen Reiser, Kristen Mahoney Shannon, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Mary A. Dwyer, and Susan D. Darlow
Jewish ancestry, 1 , 2 , 4 , 5 providing some evidence to support population-based genetic testing among the Ashkenazi Jewish population. However, the panel raised concerns about the demand on genetic counseling resources, the preparedness of healthcare
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Ying L. Liu and Zsofia K. Stadler
, microsatellite instability. The advantage of a tumor-only approach is efficiency, because germline DNA is not directly interrogated, and the necessary informed consents, privacy protections, and pretesting/posttesting genetic counseling inherent to traditional
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer
Caiqian Cropper, Ashley Woodson, Banu Arun, Carlos Barcenas, Jennifer Litton, Sarah Noblin, Diane Liu, Minjeong Park, and Molly Daniels
counseling at our institution between March 31, 2013, and June 30, 2014. Because of the rarity of male breast cancer, all male patients with breast cancer seen for genetic counseling were included (genetic testing dates ranged from September 9, 1999–June 30
Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies
Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H.L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, and Heather H. Cheng
, particularly at higher variant allelic fraction, prompted genetic counseling referral. Dedicated germline genetic testing confirmed that the BRCA2 c.9196C>T was a heterozygous germline variant and led to cascade genetic testing of his family. His older sister
